ROCKVILLE, Md., June 1, 2015 /PRNewswire/ -- Synthetic Biologics,
Inc. (NYSE MKT: SYN), a clinical-stage company focused on
developing therapeutics to protect the microbiome while targeting
pathogen-specific diseases, today announced that the Company is
hosting its Microbiome Analyst & Investor Meeting on
Wednesday, June 3, 2015, at the Grand
Hyatt New York Hotel. Synthetic Biologics will provide an overview
of the clinical, regulatory and commercial pathways of the
Company's clinical-stage therapeutics, including SYN-010 to reduce
the impact of methane producing organisms on irritable bowel
syndrome with constipation (IBS-C), and SYN-004 to protect the gut
microbiome from intravenous (IV) beta-lactam antibiotics for the
prevention of C. difficile infection.
The program includes presentations by Synthetic Biologics'
President and Chief Executive Officer Jeffrey Riley and Senior Vice President,
Clinical & Regulatory Affairs, Joseph
Sliman, M.D., MPH. In addition, keynote speakers,
Mark Pimentel, M.D., FRCP(C),
Director, GI Motility Program and Laboratory, and Professor of
Medicine at Cedars-Sinai in Los Angeles, and Professor Mark H.
Wilcox, M.D., FRCPath, Consultant/Head of Microbiology at the Leeds
Teaching Hospitals NHS Trust, Professor of Medical Microbiology at
the University of Leeds and the Lead on C. difficile
Infection, Public Health England (PHE), will discuss Synthetic
Biologics' novel approaches to treating IBS-C and preventing C.
difficile.
A live webcast of the presentations will begin on
June 3, 2015, at 9:00 a.m. EDT and the webcast is scheduled to
conclude by 11:30 a.m. EDT. The live
webcast of the event will be available via the internet at:
https://tallen.webcasts.com/starthere.jsp?ei=1066312. An archived
webcast will be available at the same website following the
meeting.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical-stage
company focused on developing therapeutics to protect the
microbiome while targeting pathogen-specific diseases. The Company
is developing an oral biologic to protect the gut microbiome from
intravenous (IV) antibiotics for the prevention of C.
difficile infection and an oral statin treatment to reduce the
impact of methane producing organisms on irritable bowel syndrome
with constipation (IBS-C). In addition, the Company is developing a
monoclonal antibody combination for the treatment of Pertussis in
collaboration with Intrexon Corporation (NYSE: XON), and a Phase 2
oral estriol drug for the treatment of relapsing-remitting multiple
sclerosis (MS) and cognitive dysfunction in MS. For more
information, please visit Synthetic Biologics' website at
www.syntheticbiologics.com.
Logo- http://photos.prnewswire.com/prnh/20130522/MM19465LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-host-microbiome-analyst--investor-meeting-300091040.html
SOURCE Synthetic Biologics, Inc.